$599
Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics

Ascletis Completes Ph2 Enrollment for ASC30 in T2DM; GSK’s Efimosfermin Breakthrough Therapy and PRIME Designations; Tandem Control-IQ+ Pregnancy Indication; Tandem Mobi Correction; Sagimet Business Updates and Stock Pricing

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, GSK, Tandem Diabetes, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home